RecruitingPhase 3NCT07473973
ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency
Studying Autosomal recessive hypophosphatemic rickets
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Inozyme Pharma
- Principal Investigator
- Medical Director, MDBioMarin Pharmaceutical
- Intervention
- INZ-701(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 0-1 years · All sexes
- Timeline
- 2025 – 2028
Study locations (8)
- Hospital Universitario Pedro Ernesto/Rio de Janeiro, Rio de Janeiro, Brazil
- Hopital Necker - Enfants Malades, Paris, France
- Gyermekgyogyaszat, DE, Debrecen, Hungary
- Azienda Ospedaliera Universitaria Meyer, Florence, Italy
- King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
- Hospital Sant Joan de Deu Edificio Consultas Externas. Unitat de Recerca, Barcelona, Esplugues de Llobregat, Spain
- Umraniye Traiing and Research Hospital, Istanbul, Turkey (Türkiye)
- Royal Manchester Children's Hospital, Manchester, United Kingdom
Collaborators
BioMarin Pharmaceutical
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07473973 on ClinicalTrials.govOther trials for Autosomal recessive hypophosphatemic rickets
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT06046820The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 DeficiencyInozyme Pharma
- RECRUITINGPHASE1NCT05734196The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 DeficiencyInozyme Pharma
See all trials for Autosomal recessive hypophosphatemic rickets →